Literature DB >> 8215867

Amantadine-induced coma.

G J Macchio1, V Ito, V Sahgal.   

Abstract

Amantadine has found use primarily as an antiviral agent and in the symptomatic treatment of parkinsonism. However, the use of amantadine for the subjective alleviation of fatigue in multiple sclerosis and in the treatment of agitated aggressive behavior in the traumatic brain injured patient has also been described. Side effects of amantadine are primarily related to the central nervous system and include hallucinations, confusion, and nightmares. Toxic manifestations include acute psychosis, coma, cardiovascular toxicity, and death. Amantadine toxicity is a particular problem in patients with renal insufficiency because 90% of an oral dose is excreted unchanged in the urine. We present a case of amantadine-induced coma in a patient with multiple sclerosis and end-stage renal disease. Moreover, this degree of amantadine toxicity was profoundly apparent at a drug level usually not associated with such a severe presentation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8215867     DOI: 10.1016/0003-9993(93)90072-i

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  8 in total

1.  Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease.

Authors:  Mariza Bortolanza; Keila D Bariotto-Dos-Santos; Maurício Dos-Santos-Pereira; Célia Aparecida da-Silva; Elaine Del-Bel
Journal:  Neurotox Res       Date:  2016-04-06       Impact factor: 3.911

Review 2.  Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.

Authors:  Nilson Carlos Ferreira Junior; Maurício Dos-Santos-Pereira; Francisco Silveira Guimarães; Elaine Del Bel
Journal:  Neurotox Res       Date:  2019-10-22       Impact factor: 3.911

3.  Case Reports Describing Amantadine Intoxication in a Rehabilitation Hospital.

Authors:  Kenjiro Kunieda; Takashi Shigematsu; Ichiro Fujishima
Journal:  Prog Rehabil Med       Date:  2017-12-27

4.  Tyrosinyl-amantadine: A New Amantadine Derivative With an Ameliorative Effect in a 6-OHDA Experimental Model of Parkinson's Disease in Rats.

Authors:  Maria Lazarova; Lyubka Tancheva; Radoslav Chayrov; Elina Tzvetanova; Albena Alexandrova; Andrey Popatanasov; Diamara Uzunova; Miroslava Stefanova; Ivanka Stankova; Reni Kalfin
Journal:  J Mol Neurosci       Date:  2022-01-28       Impact factor: 3.444

5.  Cardiotoxicity after massive amantadine overdose.

Authors:  Michael Schwartz; Manish Patel; Ziad Kazzi; Brent Morgan
Journal:  J Med Toxicol       Date:  2008-09

6.  Influenza prophylaxis in the long-term care facility: a case-control study of the risk factors for adverse drug reactions to amantadine.

Authors:  Michael J Dolamore
Journal:  Curr Ther Res Clin Exp       Date:  2003-11

7.  Amantadine intoxication despite moderate renal dysfunction: A case of combined use with donepezil.

Authors:  Kouji Okada; Takashi Uno; Miho Utsumi; Kensuke Usui; Masashi Nakamura; Ichiro Nakashima; Eiji Suzuki; Yoshiteru Watanabe
Journal:  Clin Case Rep       Date:  2020-03-16

8.  Placebo-controlled trial of oral amantadine and zolpidem efficacy on the outcome of patients with acute severe traumatic brain injury and diffuse axonal injury.

Authors:  Sajad Shafiee; Saeed Ehteshami; Mahmood Moosazadeh; Saeed Aghapour; Kaveh Haddadi
Journal:  Caspian J Intern Med       Date:  2022
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.